DOI QR코드

DOI QR Code

제 1상 임상시험에서 다양한 멈춤 규칙을 이용한 최대허용용량 추정법

Maximum tolerated dose estimations using various stopping rules in phase I clinical trial

  • 전소영 (가톨릭대학교 의생명.건강과학과) ;
  • 김동재 (가톨릭대학교 의생명.건강과학과)
  • Jeon, Soyoung (Department of Biomedicine.health science, The Catholic University of Korea) ;
  • Kim, Dongjae (Department of Biomedicine.health science, The Catholic University of Korea)
  • 투고 : 2021.11.23
  • 심사 : 2022.01.05
  • 발행 : 2022.04.30

초록

제1상 임상시험은 '투약 용량 발견 시험(dose finding study)'라고도 불리는데 동물 실험 또는 시험관 실험을 통하여 개발된 신약 물질을 사람에게 시험하는 첫 단계이다. 제 1상 임상시험의 목적 중 하나는 환자에게 허용할 수 있으면서 최대의 효능을 가진 복용량인 최대허용용량(maximum tolerated dose, MTD)을 결정하는 것이다. 본 논문에서는 다양한 멈춤 규칙을 이용한 MTD 추정법들을 소개한다. 또한 모의실험을 통해 SM3, NM, Rim, J3, BSM 방법을 비교하고 효율적인 MTD 추정법에 대해 고찰한다. 모의실험 결과 BSM방법이 목표독성확률에 가장 가깝게 MTD를 추정하는 것으로 나타났다. 또한 J3방법의 피험자 수가 가장 적었다. 이러한 결과는 두 방법의 멈춤 규칙의 특성 때문이라고 판단되는데 BSM방법은 독성 반응이 있을 때 같은 용량에 피험자를 2명 또는 1명을 추가한다. 또한 J3방법은 동일한 용량에 할당되는 최대 피험자 수가 다른 방법에 비해 적다. 이러한 특성들을 결합하여 추정법을 개선한다면 더 효율적으로 MTD를 추정할 수 있을 것이다. 특히 BSM방법의 멈춤 규칙을 이용하면서 총 피험자 수를 줄일 수 있다면 적은 수의 피험자로 정확한 추정이 가능할 것이다.

Phase I clinical trial is called 'Dose finding study'. It is first step of experimenting on humans with new drugs developed through animal experiments or vitro experiments. The important area of interest in designing Phase I clinical trial is determining the dose that acceptable level to the patients and provides the greatest efficacy. In this paper, we explain about methods to determine the maximum tolerated dose using various stopping rules. The SM3, NM, Rim, J3, BSM methods are compared through simulation. And we consider how the methods might be reformed. As a result of the simulation, BSM estimated the MTD closest to the target toxicity probability. J3 method required the least number of subjects. These results are due to the feature of the stopping rules of both methods. The BSM adds 2 or 1 subject at the same dose level when there is a toxic reaction. In addition, the J3 method has a smaller number of subjects than the other methods. If the methods are improved by combining these features, MTD can be estimated more efficiently. If the total number of subjects can be reduced while using the stopping rule of the BSM, accurate estimation is possible for a small number of subjects.

키워드

참고문헌

  1. Ahn C (1998). An evaluation of phase I cancer clinical trial designs, Statistics in Medicine, 17, 1537-1549. https://doi.org/10.1002/(SICI)1097-0258(19980730)17:14<1537::AID-SIM872>3.0.CO;2-F
  2. Dixon WJ and Mode AM (1948). A method for obtaining and analyzing sensitivity data, Journal of the American Statistical Association, 43, 109-128. https://doi.org/10.1080/01621459.1948.10483254
  3. Efron B (1971). Forcing a sequential experiment to be balanced, Biometrika, 58, 403-417. https://doi.org/10.1093/biomet/58.3.403
  4. Goodman SN, Zahurak ML, and Piantadosi S (1995). Some practical improvements in the continual reassessment method for phase I studies, Statistics in Medicine, 14, 1149-1161. https://doi.org/10.1002/sim.4780141102
  5. Jeon S and Kim D (2020). Maximum tolerated dose estimation by Biased coin design and stopping rule in phase I clinical trial, The Korean Journal of Applied Statistics, 33, 137-145. https://doi.org/10.5351/KJAS.2020.33.2.137
  6. Kim Y and Kim D (2012). Maximum tolerated dose estimation applied biased coin design in a phase I clinical trial, Communications for Statistical Applications and Methods, 19, 877-884. https://doi.org/10.5351/CKSS.2012.19.6.877
  7. Korn EL, Midthune D, Chen TT, Rubinstein LV, Christian MC, and Simon RM (1994). A comparison of two phase I trail designs, Statistics in Medicine, 13, 1799-1806. https://doi.org/10.1002/sim.4780131802
  8. Lee N and Kim D (2012). Two-stage maximum tolerated dose estimation by stopping rule in phase I clinical trial, Communications for Statistical Applications and Methods, 19, 57-64. https://doi.org/10.5351/CKSS.2012.19.1.057
  9. O'Quigley J and Chevret S (1991). Method for dose finding studies in cancer clinical trials: a review and results of a Monte Carlo study, Statistics in Medicine, 10, 1647-1664. https://doi.org/10.1002/sim.4780101104
  10. Park I (1999). The estimation of maximal tolerated dose in sequential phase I clinical trials (Master's Thesis of Science), The Catholic University of Korea.
  11. Park J and Kim D (2012). Adjusted maximum tolerated dose estimation by stopping rule in phase I clinical trial, Journal of the Korean Data and Information Science Society, 23, 1085-1091 https://doi.org/10.7465/jkdi.2012.23.6.1085
  12. Storer BE (1989). Design and analysis of phase I clinical trials, Biometrics, 45, 925-937. https://doi.org/10.2307/2531693
  13. Storer BE (2001). An evaluation of phase I clinical trial designs in the continuous dose response setting, Statistics in Medicine, 20, 2399-2408. https://doi.org/10.1002/sim.903